Axsome Therapeutics (AXSM) Receiving Favorable Press Coverage, Study Shows

Media headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Axsome Therapeutics earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.5759490975231 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Shares of Axsome Therapeutics stock traded down $0.05 during mid-day trading on Monday, hitting $2.65. 126,292 shares of the stock traded hands, compared to its average volume of 433,104. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.90 and a current ratio of 2.90. Axsome Therapeutics has a 12 month low of $2.45 and a 12 month high of $6.45. The stock has a market cap of $68.83, a price-to-earnings ratio of -2.05 and a beta of -0.20.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Wednesday, March 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.04. equities research analysts anticipate that Axsome Therapeutics will post -0.26 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on AXSM. Zacks Investment Research lowered shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. ValuEngine upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald set a $13.00 price target on shares of Axsome Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $16.90.

ILLEGAL ACTIVITY WARNING: “Axsome Therapeutics (AXSM) Receiving Favorable Press Coverage, Study Shows” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3278863/axsome-therapeutics-axsm-receiving-favorable-press-coverage-study-shows.html.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Schneider Electric  Given a €88.00 Price Target by Societe Generale Analysts
Schneider Electric Given a €88.00 Price Target by Societe Generale Analysts
Essilor International  Given a €104.40 Price Target at JPMorgan Chase
Essilor International Given a €104.40 Price Target at JPMorgan Chase
Berenberg Bank Analysts Give Danone  a €72.50 Price Target
Berenberg Bank Analysts Give Danone a €72.50 Price Target
Zooplus  Given a €140.00 Price Target by Kepler Capital Markets Analysts
Zooplus Given a €140.00 Price Target by Kepler Capital Markets Analysts
Reviewing Government Properties Income Trust  and Innovative Industrial
Reviewing Government Properties Income Trust and Innovative Industrial
Sky Solar  & Its Rivals Head-To-Head Comparison
Sky Solar & Its Rivals Head-To-Head Comparison


© 2006-2018 Ticker Report. Google+.